Glucose monitoring for brain tumor patients
Part of Cancer clinical trials.
This study tests whether using a continuous glucose monitor (a small device that tracks blood sugar levels) can help manage high blood sugar in people newly diagnosed with glioblastoma, a type of brain cancer. It aims to see if this monitoring can improve overall health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be newly diagnosed with glioblastoma (a type of brain cancer) based on MRI scans.
- You need to be generally active and able to care for yourself (score of 70 or above on a standard scale).
- Your blood counts (white cells, platelets, hemoglobin) and liver/kidney function must be within certain limits.
- You should be willing to wear a continuous glucose monitor and attend diet counseling sessions.
- You cannot have had recurrent glioblastoma, type 1 diabetes, eating disorders, or substance abuse in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether certain details on brain scans can help doctors better predict how brain cancer (glioblastoma) will progress. You may be eligible if you are newly diagnosed with this type of cancer and plan to receive standard treatment.
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial studies whether a blood test can track the progress of a type of brain tumor called a grade 4 diffuse glioma. It may offer a less invasive way to monitor these tumors after surgery.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.